title: Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.
abstract: OBJECTIVE
  Recently, high serum DPP-4 activity was found in patients with NAFLD. Therefore, the possibility of NAFLD adversely influencing the therapeutic effect afforded by DPP-4 inhibitors in type 2 diabetic patients was suggested.
  
  
  METHODS
  A total of 20 type 2 DM patients with NAFLD and 85 type 2 DM patients without NAFLD were enrolled in the present study. The patients were administered sitagliptin at the dose of 50 mg/day for 12 weeks.
  
  
  RESULTS
  The change in HbA1c from the baseline following treatment with sitagliptin was -0.47% (4 weeks), -0.73% (8 weeks) and -0.88% (12 weeks) in the type 2 DM patients with NAFLD and -0.26% (4 weeks), -0.41% (8 weeks) and -0.49% (12 weeks) in type 2 DM without NAFLD. The changes in the HbA1c from the baseline after sitagliptin treatment for 8 and 12 weeks were significantly greater in type 2 DM patients with NAFLD than in type 2 DM patients without NAFLD.
  
  
  CONCLUSIONS
  The results of this study suggest that NAFLD might adversely affect the therapeutic effect afforded by sitagliptin treatment in patients with type 2 DM. NAFLD may be an independent predictor of the effect of sitagliptin in patients with type 2 DM.
authors.affiliation: Iwasaki Naika Clinic, Yokohama, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Wataru
authors.initials: W
authors.lastname: Tomeno
authors.forename: Masato
authors.initials: M
authors.lastname: Yoneda
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Jun
authors.initials: J
authors.lastname: Shirakawa
authors.forename: Kento
authors.initials: K
authors.lastname: Imajo
authors.forename: Keigo
authors.initials: K
authors.lastname: Kawashima
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005234:Fatty Liver / Q000150:complications*; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D011719:Pyrazines / Q000627:therapeutic use*; D012044:Regression Analysis; D012189:Retrospective Studies; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles; C517652:hemoglobin A1c protein, human